|
|
In the ever more complex and fast trading world with direct market access (DMA) where trading can be done from a remote location, who polices fraud? Edward Stileman, direct of R3cognition, a market surveillance company, explains to Jeremy Grant that much of this role has been delegated to brokers, many of which aren’t ready for the responsibility.
|
|
Video Length: 351
Date Found: July 05, 2011
Date Produced:
|
|
 FT.com |
July 15, 2011
John Martin, chief executive of Gilead, the US pharmaceuticals company behind flu and HIV drugs, places long or short bets on the news agenda from an HIV cure and Obama to US R&D and Google.
|
 FT.com |
July 15, 2011
The rich are getting richer but so are the poor. It is the workers in the middle who are feeling the pinch. Prof Alan Manning from the London School of Economics says technology is the main reason why middle ranking jobs are on the decline. However, he also thinks that banking regulations put ...
|
 FT.com |
July 15, 2011
Kevin Corrigan, head of credit at Lombard Odier Investment Managers, thinks there is an under-explored niche opportunity between investment grade and high yield bonds and that is why his company has launched its 5Bs fund. He says the risk characteristics of triple B and double B rated bonds are ...
|
 FT.com |
July 15, 2011
Gilead was founded 30 years ago and now the biotech start-up has become a leading US pharmaceutical company behind flu and HIV treatments, Tamiflu and Atripla. Pharmaceuticals correspondent Andrew Jack assesses chief executive John Martin’s views on drug access for poorer countries, innovation ...
|
 FT.com |
July 15, 2011
Gilead was founded 30 years ago and now the biotech start-up has become a leading US pharmaceutical company behind flu and HIV treatments, Tamiflu and Atripla. Pharmaceuticals correspondent Andrew Jack assesses chief executive John Martin’s views on drug access for poorer countries, innovation ...
|
|
|
|
|
|
Featured
Content
Featuring websites that enhance the internet user’s experience.
|